The dual blockade of BRAF and MEK with dabrafenib and trametinib, an effective strategy in BRAF-mutated metastatic melanoma, improved these results with a response rate of 47% (20 responses out of 43 patients) at the interim analysis of the phase II ROAR basket trial [63], leading to the FDA approval of dabrafenib-trametinib combination in BRAFV600E mutated advanced tumours, including BTC [39] (Table 1). This evidence concerns the gene BRAF and neoplasm.